EA002347B1 - Замещенные трициклические соединения - Google Patents

Замещенные трициклические соединения Download PDF

Info

Publication number
EA002347B1
EA002347B1 EA199900301A EA199900301A EA002347B1 EA 002347 B1 EA002347 B1 EA 002347B1 EA 199900301 A EA199900301 A EA 199900301A EA 199900301 A EA199900301 A EA 199900301A EA 002347 B1 EA002347 B1 EA 002347B1
Authority
EA
Eurasian Patent Office
Prior art keywords
methyl
carbamoylcarbazol
hydroxyacetic acid
alkyl
phenyl
Prior art date
Application number
EA199900301A
Other languages
English (en)
Russian (ru)
Other versions
EA199900301A3 (ru
EA199900301A2 (ru
Inventor
Бенджамин Алан Андерсон
Николас Джеймс Бах
Жоли Анн Бастиан
Нэнси Кей Харн
Ричард Вальтц Харпер
Гари Алан Хайт
Майкл Дин Кинник
Хо-Шен Лин
Ричард Джеймс Лончарик
Джон МакНейлл МакДжилл III
Эдвард Дэвид Михелик
Джон Майкл мл. Морин
Майкл ЛеРой Филлипс
Майкл Энрико Ричетт
Дэниел Джон Солл
Джейсон Скотт Сойер
Ричард Вальтер Шевитц
Роберт Теодор Василефф
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA199900301A2 publication Critical patent/EA199900301A2/ru
Publication of EA199900301A3 publication Critical patent/EA199900301A3/ru
Publication of EA002347B1 publication Critical patent/EA002347B1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/80[b, c]- or [b, d]-condensed
    • C07D209/82Carbazoles; Hydrogenated carbazoles
    • C07D209/88Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/58[b]- or [c]-condensed
    • C07D209/70[b]- or [c]-condensed containing carbocyclic rings other than six-membered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EA199900301A 1998-04-17 1999-04-16 Замещенные трициклические соединения EA002347B1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6232898A 1998-04-17 1998-04-17

Publications (3)

Publication Number Publication Date
EA199900301A2 EA199900301A2 (ru) 1999-10-28
EA199900301A3 EA199900301A3 (ru) 2000-04-24
EA002347B1 true EA002347B1 (ru) 2002-04-25

Family

ID=22041763

Family Applications (2)

Application Number Title Priority Date Filing Date
EA199900301A EA002347B1 (ru) 1998-04-17 1999-04-16 Замещенные трициклические соединения
EA199900303A EA002816B1 (ru) 1998-04-17 1999-04-16 Производные карбазола

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA199900303A EA002816B1 (ru) 1998-04-17 1999-04-16 Производные карбазола

Country Status (30)

Country Link
EP (2) EP0952149B1 (https=)
JP (2) JPH11322713A (https=)
KR (2) KR19990083232A (https=)
CN (1) CN1149193C (https=)
AR (2) AR018593A1 (https=)
AT (2) ATE271037T1 (https=)
AU (2) AU753436B2 (https=)
BR (2) BR9901279A (https=)
CA (2) CA2269246C (https=)
CO (2) CO5011054A1 (https=)
CZ (2) CZ137099A3 (https=)
DE (2) DE69917833T2 (https=)
DK (1) DK0950657T3 (https=)
DZ (1) DZ2769A1 (https=)
EA (2) EA002347B1 (https=)
ES (2) ES2222663T3 (https=)
HU (2) HUP9901220A3 (https=)
ID (2) ID23287A (https=)
IL (2) IL129483A0 (https=)
NO (2) NO314400B1 (https=)
NZ (3) NZ507564A (https=)
PE (2) PE20000432A1 (https=)
PL (2) PL332566A1 (https=)
PT (1) PT950657E (https=)
SG (2) SG81977A1 (https=)
SI (1) SI0950657T1 (https=)
TR (2) TR199900843A2 (https=)
TW (1) TWI238160B (https=)
YU (2) YU19199A (https=)
ZA (2) ZA992771B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2497806C9 (ru) * 2007-04-27 2014-01-20 Этерна Центарис ГмбХ Производные тетрагидрокарбазола, фармацевтическая композиция и лекарственное средство на их основе, способ лечения и/или профилактики физиологических и/или патологических состояний, опосредованных lhrh рецептором, посредством вышеназванных производных

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001513555A (ja) * 1997-08-28 2001-09-04 イーライ・リリー・アンド・カンパニー 非リウマチ様関節炎の処置方法
DZ2769A1 (fr) * 1998-04-17 2003-12-01 Lilly Co Eli Composés tricycliques substitués.
AU1940800A (en) * 1998-12-21 2000-07-12 Eli Lilly And Company Combination therapy for the treatment of sepsis
US6706752B1 (en) 1999-07-19 2004-03-16 Eli Lilly And Company sPLA2 inhibitors
CA2379208A1 (en) * 1999-07-19 2001-01-25 Eli Lilly & Company Spla2 inhibitors
ES2294003T3 (es) * 2000-06-29 2008-04-01 Anthera Pharmaceuticals, Inc. Remedios contra el cancer.
AU2001267825A1 (en) 2000-06-29 2002-01-08 Shionogi And Co., Ltd. Remedies for cirrhosis
AU2001267826A1 (en) * 2000-06-29 2002-01-08 Shionogi And Co., Ltd. Remedies for alzheimer's disease
CN1450893A (zh) * 2000-07-14 2003-10-22 伊莱利利公司 治疗脓毒症的方法
US6872743B2 (en) 2000-12-18 2005-03-29 Eli Lilly And Company sPLA2 inhibitors
JP2004525154A (ja) * 2001-03-28 2004-08-19 イーライ・リリー・アンド・カンパニー sPLA2インヒビターとしての置換カルバゾール
AUPS282602A0 (en) 2002-06-07 2002-06-27 Garvan Institute Of Medical Research Method of inhibiting cell proliferation
DE10249055A1 (de) 2002-10-22 2004-05-06 Bayer Cropscience Ag 2-Phenyl-2-substituierte-1,3-diketone
JO3598B1 (ar) 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
MX2010010471A (es) 2008-03-26 2010-10-20 Daiichi Sankyo Co Ltd Derivado de tetrahidroisoquinolina novedoso.
CA2721060A1 (en) 2008-04-09 2009-10-15 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
WO2010084402A2 (en) * 2009-01-22 2010-07-29 Orchid Research Laboratories Ltd. Heterocyclic compounds as phosphodiesterase inhibitors
WO2010118155A1 (en) 2009-04-07 2010-10-14 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
WO2010118159A1 (en) 2009-04-07 2010-10-14 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
RU2015143910A (ru) 2010-02-03 2018-12-28 Инфинити Фармасьютикалз, Инк. Ингибиторы амид-гидролазы жирных кислот
AR088377A1 (es) 2011-10-20 2014-05-28 Siena Biotech Spa Proceso para la preparacion de 6-cloro-2,3,4,9-tetrahidro-1h-carbazol-1-carboxamida y compuestos intermedios de esta
CN102816107B (zh) * 2012-08-20 2015-06-03 东南大学 咔唑衍生物及其制备方法与用途
KR20150088802A (ko) 2012-11-30 2015-08-03 지이 헬쓰케어 리미티드 트리시클릭 인돌 유도체의 결정화 방법
IN2015DN03939A (https=) * 2012-11-30 2015-10-02 Ge Healthcare Ltd
WO2016116527A1 (de) * 2015-01-20 2016-07-28 Cynora Gmbh Organische moleküle, insbesondere zur verwendung in optoelektronischen bauelementen
CN108707104A (zh) * 2018-08-07 2018-10-26 北京恒信卓元科技有限公司 2-氯-1h-咔唑-1,4(9h)-二酮的合成方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU281473A1 (ru) * Московский ордена Ленина , ордена Трудового КраснйгргЗнаШйй Способ получения 1-{3 аминоалкил)-2,3-
US3939177A (en) * 1972-11-22 1976-02-17 Sterling Drug Inc. 4-Aminomethyl-9-benzyl-1,2,3,4-tetrahydrocarbazoles
WO1993001169A2 (en) * 1991-07-05 1993-01-21 Merck Sharp & Dohme Limited Aromatic compounds, pharmaceutical compositions containing them and their use in therapy
EP0532456A1 (de) * 1991-08-12 1993-03-17 Ciba-Geigy Ag 1-Acylpiperidinverbindungen und ihre Verwendung als Substanz P Artagonisten
EP0620215A1 (en) * 1993-04-16 1994-10-19 Eli Lilly And Company 1H-indole-3-acetamide derivatives as sPLA2 inhibitors
EP0620214A1 (en) * 1993-04-16 1994-10-19 Eli Lilly And Company 1H-indole-3-acetic acid hydrazide sPLA2 inhibitors
EP0839806A1 (en) * 1996-10-30 1998-05-06 Eli Lilly And Company Substituted tricyclics

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3579534A (en) * 1969-05-09 1971-05-18 American Cyanamid Co Tetrahydrocarbazolecarboxylates
US3979391A (en) * 1972-11-22 1976-09-07 Sterling Drug Inc. 1,2,3,4-Tetrahydrocarbazoles
US5420289A (en) * 1989-10-27 1995-05-30 American Home Products Corporation Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase
PT95692A (pt) * 1989-10-27 1991-09-13 American Home Prod Processo para a preparacao de derivados de acidos indole-,indeno-,piranoindole- e tetra-hidrocarbazole-alcanoicos, ou quais sao uteis como inibidores de pla2 e da lipoxigenase
DE69610793T2 (de) * 1995-06-23 2001-05-03 Eli Lilly And Co., Indianapolis 6-Subsitituierte-1,2,3,4-tetrahydro-9H-Carbazole und 7-substituierte-1OH-Cyclohepta(7,6-B)-Indole
AU1289797A (en) * 1995-12-13 1997-07-03 Eli Lilly And Company Naphthyl acetamides as spla2 inhibitors
AU9664198A (en) * 1997-09-26 1999-04-23 Eli Lilly And Company Method for the treatment of cystic fibrosis
CA2310250A1 (en) * 1997-11-14 1999-05-27 August Masaru Watanabe Treatment for alzheimer's disease
DZ2769A1 (fr) * 1998-04-17 2003-12-01 Lilly Co Eli Composés tricycliques substitués.

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU281473A1 (ru) * Московский ордена Ленина , ордена Трудового КраснйгргЗнаШйй Способ получения 1-{3 аминоалкил)-2,3-
US3939177A (en) * 1972-11-22 1976-02-17 Sterling Drug Inc. 4-Aminomethyl-9-benzyl-1,2,3,4-tetrahydrocarbazoles
WO1993001169A2 (en) * 1991-07-05 1993-01-21 Merck Sharp & Dohme Limited Aromatic compounds, pharmaceutical compositions containing them and their use in therapy
EP0532456A1 (de) * 1991-08-12 1993-03-17 Ciba-Geigy Ag 1-Acylpiperidinverbindungen und ihre Verwendung als Substanz P Artagonisten
EP0620215A1 (en) * 1993-04-16 1994-10-19 Eli Lilly And Company 1H-indole-3-acetamide derivatives as sPLA2 inhibitors
EP0620214A1 (en) * 1993-04-16 1994-10-19 Eli Lilly And Company 1H-indole-3-acetic acid hydrazide sPLA2 inhibitors
EP0839806A1 (en) * 1996-10-30 1998-05-06 Eli Lilly And Company Substituted tricyclics

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF MEDICINAL CHEMISTRY, vol. 36. no. 14, 1993, WASHINGTON US, pages 2044-2045, XP002003038, A. MACLEOD ET AL.: "N-acyl-l-tryptophan benzyl esters: potent substance P receptor antagonists", see page 2044, left-hand column, line 1 - line 34; table I *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2497806C9 (ru) * 2007-04-27 2014-01-20 Этерна Центарис ГмбХ Производные тетрагидрокарбазола, фармацевтическая композиция и лекарственное средство на их основе, способ лечения и/или профилактики физиологических и/или патологических состояний, опосредованных lhrh рецептором, посредством вышеназванных производных

Also Published As

Publication number Publication date
CN1149193C (zh) 2004-05-12
NO991821D0 (no) 1999-04-16
AU753547B2 (en) 2002-10-24
SI0950657T1 (en) 2005-02-28
PL332565A1 (en) 1999-10-25
CA2269262A1 (en) 1999-10-17
CA2269246C (en) 2009-08-25
TWI238160B (en) 2005-08-21
HU9901220D0 (en) 1999-06-28
EA199900301A3 (ru) 2000-04-24
EP0952149A2 (en) 1999-10-27
AU2381999A (en) 1999-10-28
HUP9901220A3 (en) 2001-11-28
YU19199A (sh) 2002-08-12
NO312240B1 (no) 2002-04-15
TR199900843A2 (xx) 2000-02-21
PE20000476A1 (es) 2000-06-02
ATE268756T1 (de) 2004-06-15
ES2222663T3 (es) 2005-02-01
AR018593A1 (es) 2001-11-28
EP0950657B1 (en) 2004-07-14
EP0950657A3 (en) 2001-08-16
EA002816B1 (ru) 2002-10-31
CZ136999A3 (cs) 1999-11-17
NZ335253A (en) 2000-11-24
CO5011054A1 (es) 2001-02-28
TR199900853A3 (tr) 1999-11-22
EP0950657A2 (en) 1999-10-20
NO314400B1 (no) 2003-03-17
SG81976A1 (en) 2001-07-24
PL332566A1 (en) 1999-10-25
AU2381799A (en) 1999-10-28
ZA992772B (en) 2002-07-16
SG81977A1 (en) 2001-07-24
YU18999A (sh) 2002-08-12
PT950657E (pt) 2004-11-30
HU9901220A (hu) 2000-04-28
ID23761A (id) 2000-05-11
DE69918590D1 (de) 2004-08-19
KR19990083232A (ko) 1999-11-25
BR9901279A (pt) 2000-05-02
PE20000432A1 (es) 2000-05-23
HU9901221D0 (en) 1999-06-28
IL129485A0 (en) 2000-02-29
EP0952149A3 (en) 2001-08-16
ID23287A (id) 2000-04-05
KR100586761B1 (ko) 2006-06-08
DE69918590T2 (de) 2005-07-21
ES2226286T3 (es) 2005-03-16
DE69917833D1 (de) 2004-07-15
DK0950657T3 (da) 2004-11-22
BR9902365A (pt) 2001-04-24
JP2000026416A (ja) 2000-01-25
DE69917833T2 (de) 2005-07-14
JPH11322713A (ja) 1999-11-24
EA199900303A2 (ru) 1999-10-28
EA199900303A3 (ru) 2000-04-24
AR018186A1 (es) 2001-10-31
KR19990083233A (ko) 1999-11-25
NO991822D0 (no) 1999-04-16
TR199900853A2 (xx) 1999-11-22
HU9901221A (hu) 2000-04-28
EA199900301A2 (ru) 1999-10-28
JP4435330B2 (ja) 2010-03-17
HUP9901221A3 (en) 2001-11-28
CZ137099A3 (cs) 1999-11-17
CA2269246A1 (en) 1999-10-17
ATE271037T1 (de) 2004-07-15
CN1253948A (zh) 2000-05-24
DZ2769A1 (fr) 2003-12-01
NO991821L (no) 1999-10-18
EP0952149B1 (en) 2004-06-09
CO5031247A1 (es) 2001-04-27
NO991822L (no) 1999-10-18
IL129483A0 (en) 2000-02-29
NZ507564A (en) 2002-10-25
AU753436B2 (en) 2002-10-17
ZA992771B (en) 2002-04-18
NZ335251A (en) 2000-11-24

Similar Documents

Publication Publication Date Title
EA002347B1 (ru) Замещенные трициклические соединения
US6177440B1 (en) Substituted tricyclics
JP2001503055A5 (https=)
EP0839806B1 (en) Substituted tricyclics
JP2004534774A (ja) プロスタグランジンD2受容体拮抗薬としてのジヒドロピロロ[1,2−a]インドールおよびテトラヒドロピリド[1,2−a]−インドール誘導体
HRP20021039A2 (en) Cyclopentanoindoles, compositions containing such compounds and methods of treatment
WO2005085214A1 (ja) ジアリール置換複素5員環誘導体
JP4435325B2 (ja) 置換三環式化合物およびそれを含有する組成物
JPH05247030A (ja) 置換インドール又はジヒドロインドールを組み込んだアンギオテンシンii拮抗薬
US6713645B1 (en) Substituted tricyclics
WO2012011549A1 (ja) P2x4受容体拮抗剤
CA2441077A1 (en) Substituted carbazoles as inhibitors of spla2
HK1024911A (en) Substituted carbazoles, process for their preparation and their use as spla2 inhibitors
KR0156948B1 (ko) 이소인다졸 화합물
HK1025091A (en) Substituted tricyclics useful in spla2 induced diseases
HUP9903545A2 (hu) Helyettesített triciklusos vegyületek, eljárás előállításukra és a vegyületeket tartalmazó gyógyászati készítmények
HK1024912A (en) Substituted carbazoles, process for their preparation and their use as spla2 inhibitors

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU